Étiquette : cannabis médical

Cannabis in the management of PTSD : a systematic review, Yasir Rehman et al., 2021

Cannabis in the management of PTSD : a systematic review, Yasir Rehman, Amreen Saini, Sarina Huang, Emma Sood, Ravneet Gill and Sezgi Yanikomeroglu AIMS Neuroscience, 2021, 8, (3), 414-434. Doi : 10.3934/Neuroscience.2021022   Abstract : Introduction : Existing reviews exploring cannabis effectiveness have numerous limitations including narrow search strategies. We systematically explored cannabis effects on PTSD symptoms, quality of life (QOL), and return to work (RTW). We also investigated harm outcomes such as adverse effects and dropouts due to adverse effects, inefficacy, and all-cause dropout rates. Methods : Our search in MEDLINE, EMBASE, PsycInfo, CINAHL, Web of Science, CENTRAL, and PubMed databases, yielded 1 eligible RCT and 10 [...]

Lire la suite

Endocannabinoid System as Therapeutic Target of PTSD : A Systematic Review, Luca Steardo, Jr. et al., 2021

Endocannabinoid System as Therapeutic Target of PTSD : A Systematic Review Luca Steardo, Jr., Elvira Anna Carbone, Giulia Menculini, Patrizia Moretti, Luca Steardo and Alfonso Tortorella Life, 2021, 11, 214. Doi : 10.3390/life11030214 Abstract : Post-Traumatic Stress Disorder (PTSD) is a complex disorder involving dysregulation of stress-related hormones and neurotransmitter systems. Research focused on the endocannabinoid system (eCBS) for anxiety and stress regulation, cognitive and emotional responses modulation and aversive memories extinction, leading to the hypothesis that it could represent a possible alternative treatment target for PTSD. In this systematic review, we summarize evidence about the efficacy and safety of medicinal cannabidiol (CBD), D9-tetrahydrocannabinol (D9-THC), and [...]

Lire la suite

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review, Laura Orsolini et al., 2019

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review Laura Orsolini, Stefania Chiappini, Umberto Volpe, Domenico De Berardis, Roberto Latini, Gabriele Duccio Papanti  and John Martin Corkery Medicina, 2019, 55, 525, 1-14 doi : 10.3390/medicina55090525 www.mdpi.com/journal/medicina Abstract : Background and Objectives : Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives [...]

Lire la suite

Circulating endocannabinoids and genetic polymorphisms as predictors of posttraumatic stress disorder symptom severity : heterogeneity in a community-based cohort, Terri A. deRoon-Cassini et al., 2022

Circulating endocannabinoids and genetic polymorphisms as predictors of posttraumatic stress disorder symptom severity : heterogeneity in a community-based cohort Terri A. deRoon-Cassini, Carisa L. Bergner, Samantha A. Chesney, Nicholas R. Schumann, Tara Sander Lee, Karen J. Brasel and Cecilia J. Hillard Translational Psychiatry, 2022, 12, 48, 1-12. Doi : 10.1038/s41398-022-01808-1   The endocannabinoid signaling system (ECSS) regulates fear and anxiety. While ECSS hypoactivity can contribute to symptoms of established post-traumatic stress disorder (PTSD), the role of the ECSS in PTSD development following trauma is unknown. A prospective, longitudinal cohort study of 170 individuals (47% non-Hispanic Caucasian and 70% male) treated at a level 1 trauma [...]

Lire la suite

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique, Dr Christian SUEUR, GRECC, version 3-5, mars 2022

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique Projet CBD Thérapeutique, GRECC, version 3-5 Dr Christian SUEUR, mars 2022 112 pages       Aujourd’hui, il n’est plus tabou au plan international de penser et d’appliquer des prescriptions de cannabinoïdes en clinique psychiatrique et addictologique.[1]   En France, lors de la première séance du C.S.S.T. « Évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis en France », le 12 décembre 2018, c’est « le membre psychiatre » du C.S.S.T., le docteur George Brousse lui-même, qui souhaitait d’emblée « que soit mentionnée l’utilisation potentielle du CBD dans les troubles psychiatriques et de l’addiction, tout en précisant [...]

Lire la suite

The Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo, Daniele Piomelli  and Ethan B. Russo, 2016

The Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo, MD Daniele Piomelli  and Ethan B. Russo Cannabis and Cannabinoid Research, 2016, Volume 1.1, 44-46. Doi : 10.1089/can.2015.29003.ebr   Dr. Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system. Previously, from 2003 to 2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex for alleviation of cancer pain unresponsive to optimized opioid treatment and studies of Epidiolex for intractable epilepsy. He has held [...]

Lire la suite

Fibromyalgia and the endocannabinoid system, John M. McPartland, 2010

Fibromyalgia and the endocannabinoid system John M. McPartland in Fibromyalgia syndrome : A practitioner’s guide to treatment, chapter 11, 2010, 263-277. Doi : 10.1016/B978-0-443-06936-9.00011-1   CHAPTER CONTENTS Introduction . . . . . . . . . . . . . . . 263 Cannabis and cannabinoid receptors . . 264 Endocannabinoids and their enzymes . 266 Nociception and pain . . . . . . . . . . 266 Around the edges of fibromyalgia . . . . 269 Enhancing the eCB system . . . . . . . 270 Other approaches . . . . . . . . . . . . 272 Conclusions . . . . [...]

Lire la suite

Cannabis sativa research trends, challenges, and new-age perspectives, Tajammul Hussain et al., 2021

Cannabis sativa research trends, challenges, and new-age perspectives Tajammul Hussain, Ganga Jeena, Thanet Pitakbut, Nikolay Vasilev, and Oliver Kayser iScience, Cell Press, 2021,24, 103391, 1-13. Doi : 10.1016/j.isci.2021.103391   SUMMARY Cannabis sativa L. has been one of the oldest medicinal plants cultivated for 10,000 years for several agricultural and industrial applications. However, the plant became controversial owing to some psychoactive components that have adverse effects on human health. In this review, we analyzed the trends in cannabis research for the past two centuries. We discussed the historical transitions of cannabis from the category of herbal medicine to an illicit drug and back to a medicinal product post-legalization. [...]

Lire la suite

Medical cannabis for severe treatment resistant epilepsy in children : a case-series of 10 patients, Rayyan Zafar, David Nutt et al., 2021

Medical cannabis for severe treatment resistant epilepsy in children : a case-series of 10 patients Rayyan Zafar, Anne Schlag, Lawrence Phillips, David J Nutt BMJ Paediatrics Open, 2021, 5, e001234. doi : 10.1136/bmjpo-2021-001234 ABSTRACT Objectives : To report the findings of a case-series of 10 children suffering with intractable epilepsies in the UK to determine the feasibility for using whole-plant cannabis medicines to treat seizures in children. Setting : This study was conducted retrospectively through collecting clinical data from caretakers and clinicians on study outcome variables. Participants were recruited through the MedCann Support and End our Pain charity groups which are patient representative groups that support children [...]

Lire la suite

The Impact of Cannabidiol on Human Brain Function : A Systematic Review, Albert Batalla et al., 2021

The Impact of Cannabidiol on Human Brain Function : A Systematic Review Albert Batalla, Julian Bos, Amber Postma and Matthijs G. Bossong Frontiers in Pharmacology, January 2021 | Volume 11 | Article 618184, 1-15. doi : 10.3389/fphar.2020.618184   Background : Accumulating evidence suggests that the non-intoxicating cannabinoid compound cannabidiol (CBD) may have antipsychotic and anxiolytic properties, and thus may be a promising new agent in the treatment of psychotic and anxiety disorders. However, the neurobiological substrates underlying the potential therapeutic effects of CBD are still unclear. The aim of this systematic review is to provide a detailed and up-todate systematic literature overview of neuroimaging studies [...]

Lire la suite